Late relapse of germ cell tumors after cisplatin-based chemotherapy

Annals of Oncology

Volumn 8, Issue 1, 1997, Pages 41-47

  Gerl, A ^a   Clemm, C ^b   Schmeller, N ^a   Hentrich, M ^c   Lamerz, R ^a   Wilmanns, W ^a,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Clinic of Oncology Bad Trissl   (Germany)

^c City Hospital Munich Harlaching   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

chemotherapy; cisplatin; germ cell tumor; late relapse; surgery

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL;

EID: 0031041148     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008253323854     Document Type: Article

References (28)

1. Einhorn LH. Treatment of testicular cancer: A new and improved model. J Clin Oncol 1990; 11: 1777-81.
2. Motzer RJ. Adjuvant chemotherapy for patients with stage II non-seminomatous testis cancer. Semin Oncol 1995; 22: 641-6.
3. Gerl A, Clemm C, Schmeller N et al. Advances in the management of metastatic non-seminomatous germ cell tumours: A single institution experience. Br J Cancer 1996; 74: 1280-5.
4. Einhorn LH. Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981; 41: 3275-80.
5. Terebelo HR, Taylor HG, Brown A et al. Late relapse of testicular cancer. J Clin Oncol 1983; 1: 566-71.
6. Embil JM,Weinerman BH, Pascoe EA. Late recurrence of testicular cancer. Can J Surg 1994; 37: 165-7.
7. Bokemeyer C, Kuczyk MA, Fichna B et al. Late relapse of testicular cancer presenting as differentiated teratoma: Report of a case and discussion of the clinical implications. Oncol Rep 1995; 2: 615-8.
8. Deleo MJ, Greco FA, Hainsworth JD et al. Late recurrences in long-term survivors of germ cell neoplasms. Cancer 1988; 62: 985-8.
9. Lianes P, Paz-Ares L, Rivera F et al. Late recurrences (LR) in malignant germ cell tumors (MGCT). Ann Oncol 1992; 3 (Suppl 5): 165 (Abstr).
10. Baniel J, Foster RS, Gonin R et al. Late relapse of testicular cancer. J Clin Oncol 1995; 13: 1170-6.
11. Gerl A, Clemm C, Kohl P et al. Adjuvant chemotherapy of stage II non-seminomatous testicular cancer. Oncol Rep 1994; 1: 209-12.
12. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 1977; 87: 293-8.
13. Gerl A, Clemm C, Hentrich M et al. Etoposide, cisplatin, bleomycin, and cyclophosphamide (ECBC) as first-line chemotherapy for poor-risk non-seminomatous germ cell tumors. Acta Oncol 1993; 32: 541-6.
14. Williams SD, Birch R, Einhorn LH et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435-40.
15. Gerl A, Clemm C, Schmeller N et al. Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours. Br J Cancer 1994; 70: 960-5.
16. Gerl A, Clemm C, Schmeller N et al. Outcome analysis after post-chemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol 1995; 6: 483-8.
17. Clemm C, Hartenstein R, Willich N et al. Vinblastine-ifosfamide-cisplatin treatment of bulky seminoma. Cancer 1986; 58: 2203-7.
18. Mencel PJ, Motzer RJ, Mazumdar M et al. Advanced seminoma: Treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol 1994; 12: 120-6.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
20. Mead GM, Stenning SP, Parkinson MC et al. The second Medical Research Council study of prognostic factors in non-seminomatous germ cell tumors. J Clin Oncol 1992; 10: 85-94.
21. Gelderman WAH, Oosterhuis JW, Schraffordt Koops H et al. Late recurrence of mature teratoma in non-seminomatous testicular tumors after PVB chemotherapy and surgery Urology 1989; 33: 10-4.
22. Gerl A, Clemm C, Schmeller N et al. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer 1995; 72: 1026-32.
23. Borge N, Fossa SD, Ous S et al. Late recurrence of testicular cancer. J Clin Oncol 1988; 6: 1248-53.
24. Carl J, Christensen TB, von der Maase H. Cisplatinum dose dependent response in germ cell cancer evaluated by tumour marker modelling. Acta Oncol 1992; 31: 749-53.
25. Gerl A, Clemm C, Kohl P et al. Testicular tumor after cisplatin-based chemotherapy for germ cell malignancy. Eur Urol 1994; 25: 216-9.
26. Germa JR, Llanos M, Tabernero JM et al. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer 1993; 72: 2491-4.
27. Baniel J, Roth BJ, Foster RS et al. Cost and risk benefit in the management of clinical stage II non-seminomatous testicular tumors. Cancer 1995; 75: 2897-903.
28. Horwich A, Norman A, Fisher C et al. Primary chemotherapy for stage II non-seminomatous germ cell tumors of the testis. J Urol 1994; 151: 72-8.